Steward Partners Investment Advisory LLC Acquires 2,589 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Steward Partners Investment Advisory LLC increased its holdings in Eli Lilly and Company by 3.6%, now owning 74,811 shares worth approximately $61.79 million, making it the company's 28th largest holding.
• In recent transactions, insider buying occurred, with Director Jamere Jackson purchasing 200 shares and EVP Daniel Skovronsky acquiring 1,000 shares, reflecting confidence in the company's financial performance.
• Eli Lilly reported a record quarterly earnings of $6.31 EPS, surpassing estimates, with revenue rising 37.6% year-over-year to $15.56 billion.

Steward Partners Investment Advisory LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 74,811 shares of the company's stock after buying an additional 2,589 shares during the period. Eli Lilly and Company makes up 0.5% of Steward Partners Investment Advisory LLC's investment portfolio, making the stock its 28th largest holding. Steward Partners Investment Advisory LLC's holdings in Eli Lilly and Company were worth $61,788,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC lifted its holdings in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Orion Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 2.5% in the 4th quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock worth $1,243,000 after purchasing an additional 40 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its holdings in shares of Eli Lilly and Company by 4.1% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock worth $49,993,000 after purchasing an additional 2,568 shares in the last quarter. Finally, Breed s Hill Capital LLC lifted its holdings in shares of Eli Lilly and Company by 212.0% in the 4th quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock worth $1,101,000 after purchasing an additional 969 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Jamere Jackson acquired 200 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Daniel Skovronsky acquired 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Finally, Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $964.88.

Eli Lilly and Company Trading Up 2.5%

Shares of Eli Lilly and Company stock opened at $701.51 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $972.53. The firm has a market cap of $663.95 billion, a PE ratio of 45.85, a P/E/G ratio of 0.98 and a beta of 0.44. The stock has a fifty day moving average price of $764.55 and a 200-day moving average price of $794.63. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the firm posted $3.92 EPS. The business's revenue was up 37.6% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.9%. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.